> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Redeemed for Alexion’s Ultomiris
- URL: https://www.fdaweb.com/priority-voucher-redeemed-for-alexions-ultomiris-2/
- Published: 2019-05-03T12:00:00.000Z
- Updated: 2026-09-15T01:24:35.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144021

*Federal Register* notice: FDA has announced the approval of product that redeemed a priority review voucher — Alexion Pharmaceuticals’ Ultomiris (ravulizumab-cwvz) that was approved 12/21/2018 for treating adult patients living with paroxysmal nocturnal hemoglobinuria. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-05-03/pdf/2019-09005.pdf?ref=fdaweb.com).